Tandem Diabetes TNDM is gaining from continued product innovations. Yet, rising costs put pressure on margins. The stock carries a Zacks Rank #3 (Hold). Tandem Diabetes is driving transformative ...
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...
Integrations help the diabetes tech world go ‘round. The latest example of this trend comes from Abbott and Tandem Diabetes Care. The companies announced today that Tandem’s t:slim X2 insulin pump ...
Tandem Diabetes Care has received the Food and Drug Administration’s green light for the Tandem Mobi insulin pump for people with diabetes aged 6 years old and older. The Tandem Mobi is fully ...
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) in Q4 CY2025, with sales up 15% year on year to $290.4 million ...
The next big thing on Tandem Diabetes Care’s technology slate is actually a very small thing. The Mobi insulin pump—which is the company's smallest device to date and, it claims, the smallest ...
Tandem Diabetes Care announced plans to link its automated insulin delivery systems with an upcoming wearable monitor from Abbott that aims to measure glucose as well as ketone levels. The dual sensor ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem ...